Necmettin Erbakan \u00dcniversitesi T\u0131p Fak\u00fcltesi \u0130\u00e7 Hastal\u0131klar\u0131 Anabilim Dal\u0131 \u00f6\u011fretim \u00fcyesi Nefrolog Prof. Dr. K\u00fcltigin T\u00fcrkmen, otozomal dominant polikistik b\u00f6brek hastal\u0131\u011f\u0131n\u0131n (ODPKD) toplumda yeterince bilinmeyen ancak ciddi sonu\u00e7lara yol a\u00e7abilen bir genetik hastal\u0131k oldu\u011funu belirtti. T\u00fcrkmen, \u201cODPKD, b\u00f6breklerde \u00e7ok say\u0131da s\u0131v\u0131 dolu kistin olu\u015fmas\u0131yla seyreden, kal\u0131tsal ve ilerleyici bir hastal\u0131kt\u0131r. D\u00fcnya genelinde her 400\u20131000 do\u011fumdan birinde g\u00f6r\u00fcl\u00fcr ve diyaliz ya da b\u00f6brek nakli gerektiren son d\u00f6nem b\u00f6brek yetmezli\u011finin en \u00f6nemli d\u00f6rt nedeninden biridir\u201d dedi.<\/p>\n
Hastal\u0131\u011f\u0131n tamamen genetik ge\u00e7i\u015fli oldu\u011funa i\u015faret eden T\u00fcrkmen, vakalar\u0131n yakla\u015f\u0131k y\u00fczde 85\u2019inin PKD1<\/strong>, y\u00fczde 15\u2019inin ise PKD2<\/strong> genindeki mutasyonlardan kaynakland\u0131\u011f\u0131n\u0131 ifade etti. T\u00fcrkmen\u2019e g\u00f6re PKD1 mutasyonu olan hastalarda hastal\u0131k daha erken ya\u015fta ve daha a\u011f\u0131r seyrederken, PKD2 mutasyonu olanlarda ilerleme genellikle daha yava\u015f oluyor. T\u00fcrkmen ayr\u0131ca ki\u015finin bu yatk\u0131nl\u0131kla do\u011fmas\u0131na ra\u011fmen kist olu\u015fumunun ya\u015fam boyunca ikinci bir tetikleyici mekanizmayla h\u0131zlanabildi\u011fini belirtti.<\/p>\n Prof. Dr. T\u00fcrkmen, ODPKD\u2019nin yaln\u0131zca b\u00f6breklerle s\u0131n\u0131rl\u0131 olmad\u0131\u011f\u0131n\u0131 vurgulayarak hastal\u0131\u011f\u0131n sistemik etkilerine dikkat \u00e7ekti. B\u00f6brek yetmezli\u011fi geli\u015fmeden \u00e7ok \u00f6nce hastalar\u0131n \u00f6nemli bir k\u0131sm\u0131nda y\u00fcksek tansiyon<\/strong> g\u00f6r\u00fclebildi\u011fini belirten T\u00fcrkmen, b\u00f6brekle ili\u015fkili s\u0131k belirtileri \u015f\u00f6yle s\u0131ralad\u0131:<\/p>\n Kronik bel ve yan a\u011fr\u0131s\u0131<\/p>\n<\/li>\n \u0130drarda kanama ve enfeksiyon ataklar\u0131<\/p>\n<\/li>\n B\u00f6brek ta\u015f\u0131 olu\u015fumu<\/p>\n<\/li>\n<\/ul>\n B\u00f6brek d\u0131\u015f\u0131 bulgulara da de\u011finen T\u00fcrkmen, karaci\u011fer kistlerinin<\/strong> en s\u0131k g\u00f6r\u00fclen b\u00f6brek d\u0131\u015f\u0131 bulgu oldu\u011funu, baz\u0131 hastalarda beyin damarlar\u0131nda anevrizma riski<\/strong> ve kalp kapak\u00e7\u0131\u011f\u0131 sorunlar\u0131<\/strong> g\u00f6r\u00fclebilece\u011fini s\u00f6yledi. Bu nedenle hastalar\u0131n \u00e7ok y\u00f6nl\u00fc de\u011ferlendirilmesi gerekti\u011fini ifade etti.<\/p>\n T\u00fcrkmen, ODPKD tan\u0131s\u0131n\u0131n \u00e7o\u011fu zaman ultrason<\/strong> ile konulabildi\u011fini, MR g\u00f6r\u00fcnt\u00fcleme<\/strong> ile b\u00f6brek hacminin \u00f6l\u00e7\u00fclmesinin hastal\u0131\u011f\u0131n ilerleyi\u015f h\u0131z\u0131n\u0131 \u00f6ng\u00f6rmede yard\u0131mc\u0131 oldu\u011funu belirtti. Aile \u00f6yk\u00fcs\u00fc olmayan ya da tan\u0131s\u0131 netle\u015fmeyen hastalarda genetik testlerin<\/strong> \u00f6nemli destek sa\u011flad\u0131\u011f\u0131n\u0131 kaydetti.<\/p>\n ODPKD\u2019yi tamamen ortadan kald\u0131ran bir tedavinin hen\u00fcz bulunmad\u0131\u011f\u0131n\u0131 belirten T\u00fcrkmen, do\u011fru y\u00f6netimle hastal\u0131\u011f\u0131n ilerleyi\u015finin yava\u015flat\u0131labildi\u011fini vurgulad\u0131. T\u00fcrkmen\u2019e g\u00f6re tedavinin temelinde; bol su t\u00fcketimi<\/strong>, tuz k\u0131s\u0131tlamas\u0131<\/strong> ve tansiyonun s\u0131k\u0131 kontrol\u00fc<\/strong> yer al\u0131yor. Uygun hastalarda kullan\u0131lan Tolvaptan<\/strong> tedavisinin b\u00f6brek hacmindeki art\u0131\u015f\u0131 yava\u015flatt\u0131\u011f\u0131 ve b\u00f6brek fonksiyon kayb\u0131n\u0131 geciktirebildi\u011fini s\u00f6yledi.<\/p>\n Tolvaptan tedavisi s\u0131ras\u0131nda d\u00fczenli izlemin \u00f6nemine de dikkat \u00e7eken T\u00fcrkmen, \u201cS\u0131k idrara \u00e7\u0131kma ve susuzluk hissi g\u00f6r\u00fclebilir; nadiren karaci\u011ferle ilgili yan etkiler ortaya \u00e7\u0131kabilece\u011fi i\u00e7in d\u00fczenli kan testleri b\u00fcy\u00fck \u00f6nem ta\u015f\u0131r\u201d uyar\u0131s\u0131nda bulundu.<\/p>\n Prof. Dr. T\u00fcrkmen, ODPKD\u2019ye y\u00f6nelik yakla\u015f\u0131m\u0131n h\u0131zla geli\u015fti\u011fini, gelecekte genetik yap\u0131ya uygun ki\u015fiselle\u015ftirilmi\u015f tedavilerin daha fazla g\u00fcndeme gelece\u011fini belirterek s\u00f6zlerini \u015fu mesajla tamamlad\u0131: \u201cErken tan\u0131, do\u011fru tedavi ve d\u00fczenli takip ile ODPKD ile ya\u015famak m\u00fcmk\u00fcnd\u00fcr.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":" Necmettin Erbakan \u00dcniversitesi T\u0131p Fak\u00fcltesi\u2019nden Nefrolog Prof. Dr. K\u00fcltigin T\u00fcrkmen, otozomal dominant polikistik b\u00f6brek hastal\u0131\u011f\u0131n\u0131n (ODPKD) san\u0131landan yayg\u0131n g\u00f6r\u00fclen ancak fark\u0131ndal\u0131\u011f\u0131 d\u00fc\u015f\u00fck, ilerleyici bir genetik hastal\u0131k oldu\u011funa dikkat \u00e7ekerek erken tan\u0131 ve d\u00fczenli takibin kritik oldu\u011funu vurgulad\u0131.<\/p>\n","protected":false},"author":6,"featured_media":7708,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[859,2238,501,101],"class_list":["post-7707","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik","tag-bobreksagligi","tag-erkentani","tag-necmettinerbakanuniversitesi","tag-saglik"],"yoast_head":"\n\u201cSadece b\u00f6brekleri de\u011fil, t\u00fcm v\u00fccudu etkiler\u201d<\/h3>\n
\n
Tan\u0131 kolay, takip hayati<\/h3>\n
\u0130lerlemesi yava\u015flat\u0131labiliyor<\/h3>\n
\u201cErken tan\u0131 ve d\u00fczenli takip ile ya\u015famak m\u00fcmk\u00fcn\u201d<\/h3>\n